check_circleStudy Completed

Pain

Bioequivalence of single dose fast release aspirin (1000 mg) tablet versus single dose of two 500 mg fast release aspirin tablets

Trial purpose

The primary objective of this study is to compare the bioavailability of a single dose of a new 1000 mg fast release ASA (acetylsalicylic acid) tablet with that of two tablets of a commercially available 500 mg fast release tablet and to test for bioequivalence of the new versus the commercial product in healthy adult subjects.

Key Participants Requirements

Sex

Both

Age

18 - 55 Years

Trial summary

Enrollment Goal
38
Trial Dates
February 2014 - March 2014
Phase
Phase 1
Could I Receive a placebo
No
Products
Bayer Advanced Aspirin (Acetylsalicylic acid, BAY1019036)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Hackensack, 07601, United States

Primary Outcome

  • AUC0-inf (area under plasma concentration versus time curve) for ASA (acetylsalicylic acid)
    date_rangeTime Frame:
    baseline (pre-dose) and 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 55 minutes and 1. 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose
    enhanced_encryption
    Safety Issue:
    No
  • AUC0-t for ASA
    date_rangeTime Frame:
    baseline (pre-dose) and 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 55 minutes and 1. 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose
    enhanced_encryption
    Safety Issue:
    No
  • Cmax (maximum plasma concentration) for ASA
    date_rangeTime Frame:
    baseline (pre-dose) and 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 55 minutes and 1. 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • AUC0-inf for SA (salicylic acid)
    date_rangeTime Frame:
    baseline (pre-dose) and 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 55 minutes and 1. 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose
    enhanced_encryption
    Safety Issue:
    No
  • AUC0-t for SA
    date_rangeTime Frame:
    baseline (pre-dose) and 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 55 minutes and 1. 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose
    enhanced_encryption
    Safety Issue:
    No
  • Cmax for SA
    date_rangeTime Frame:
    baseline (pre-dose) and 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 55 minutes and 1. 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose
    enhanced_encryption
    Safety Issue:
    No
  • t1/2 for ASA and SA
    date_rangeTime Frame:
    baseline (pre-dose) and 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 55 minutes and 1. 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose
    enhanced_encryption
    Safety Issue:
    No
  • tmax for ASA and SA
    date_rangeTime Frame:
    baseline (pre-dose) and 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 55 minutes and 1. 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose
    enhanced_encryption
    Safety Issue:
    No
  • Lambda(z) (terminal rate constant) for ASA and SA
    date_rangeTime Frame:
    baseline (pre-dose) and 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 35, 40, 45, 50, 55 minutes and 1. 1.25, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose
    enhanced_encryption
    Safety Issue:
    No

Trial design

An Open Label, Randomized, Two-Way Crossover Trial to assess the Bioequivalence of a single oral dose of a 1000 mg Fast Release Aspirin Tablet versus Two 500 mg Fast Release Aspirin Tablets in healthy male and female subjects
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Open Label
Assignment
Crossover Assignment
Trial Arms
2